This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (6)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2002;287:1640.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved ibritumomab tiuxetan (Zevalin, IDEC Pharmaceutical Corp, San Diego) as part of a two-step regimen for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma, including patients with follicular non-Hodgkin lymphom refractory to rituximab (Rituxan, Genentech Inc, San Francisco).

Zevalin is an immunoconjugate that combines the linker-chelator tiuxetan with the monoclonal antibody ibritumomab, directed against the CD (cluster designation)–20 antigen restricted to B lymphocytes. The chelator allows for the antibody to be conjugated to a radioisotope. Step 1 of the regimen includes one infusion of rituximab followed by Indium-111 Zevalin. Step 2, administered 7-9 days later, consists of a second infusion of rituximab followed by Yttrium-90 Zevalin.

The safety and effectiveness of the Zevalin regimen were evaluated in two multicenter trials. Study 1was a single-arm trial that included 54 patients with relapsed follicular lymphoma who did not respond to their last . . . [Full Text of this Article]